Antagonism of the chemokine receptor CCR2 has been investigated in various fields of experimental cardiology and vascular medicine, including inhibition of restenosis [27, 28], diet-induced insulin resistance [17, 29], and hypertensive atherosclerosis [30, 31]; here, we examined its possible applicability to post-MI therapy. This evidence concerns the gene CCR2 and myocardial infarction.